Genetic Polymorphism of 5,10-Methylenetetrahydrofolate Reductase (MTHFR) as a Risk Factor for Coronary Artery Disease
Authors:
- 15 April 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 95 (8) , 2032-2036
Abstract
Background Epidemiological studies have identified hyperhomocyst(e)inemia as an independent risk factor for coronary artery disease (CAD). Recently, the alanine/valine ( A/V ) polymorphism of the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene, one of the key enzymes catalyzing remethylation of homocysteine, has been reported. The VV genotype correlates with increased plasma homocyst(e)ine levels as a result of the reduced activity and increased thermolability of this enzyme. In this study, we examined the distribution of the MTHFR genotypes in Japanese men and the association between the VV genotype and CAD. Methods and Results The diagnoses of CAD of all the studied patients were confirmed by coronary angiography. The MTHFR genotype was analyzed by PCR followed by Hin fI digestion. In 778 healthy male subjects, the frequency of the V allele was 0.33, comparable to that in a French Canadian population. In 362 patients with CAD, the VV genotype was significantly more frequent than in control subjects (16% versus 10%, P =.0067). The association of the VV genotype with CAD was further increased in patients with ≥99% stenotic lesions (18%, P =.0010), whereas no significant association with the VV genotype was observed in patients without a ≥99% stenosis. When the genotype frequency was compared among patients with different numbers of stenotic coronary arteries, the frequency of the VV genotype was significantly higher in patients with triple-vessel disease (26%) than in patients with single- or double-vessel disease (15% and 14%, respectively). Conclusions The VV genotype of MTHFR was also common in the Japanese population and was significantly associated with CAD. The frequency of this genotype in particular was correlated with the severity of disease. The VV genotype associated with a predisposition to increased plasma homocyst(e)ine levels may represent a genetic risk factor for CAD.Keywords
This publication has 27 references indexed in Scilit:
- Homocysteine and coronary atherosclerosisJACC, 1996
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Plasma homocysteine in acute myocardial infarction: homocysteine‐lowering effect of folic acidJournal of Internal Medicine, 1995
- Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells.Journal of Clinical Investigation, 1993
- Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism.Journal of Clinical Investigation, 1993
- Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor.Journal of Clinical Investigation, 1993
- Hyperhomocysteinemia: An Independent Risk Factor for Vascular DiseaseNew England Journal of Medicine, 1991
- Homocysteine and myocardial infarctionAtherosclerosis, 1988
- Heterozygosity for Homocystinuria in Premature Peripheral and Cerebral Occlusive Arterial DiseaseNew England Journal of Medicine, 1985
- Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis.Journal of Clinical Investigation, 1976